BioTech
STAT+: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses. Total revenue was slightly weak overall, but sales were stronger for two newly launched medicines — Leqembi and Skyclarys — that matter most to the biotech’s turnaround effort.
Shares rose 5% to $202 in early trading.
Here’s what you need to know from Biogen’s earnings and conference call:
